Haematological malignancies: at the forefront of immunotherapeutic innovation
Open accessThe DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Abstract
The recent successes of cancer immunotherapies have stimulated interest in the potential widespread application of these approaches; haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit these mechanisms for therapeutic purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It has recently emerged that factors beyond tumor genomics influence cancer development and therapeutic responses (4–7), including host factors such as the gastrointestinal (gut) microbiome (8–10).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–216 of 216
Jain, N., Reuben, J. M., Kantarjian, H. M., Li, C., Gao, H., Lee, B.-N., Cohen, E. N., Ebarb, T., Scheinberg, D. A., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24468 · Cited by 54
Ai, W. Z., Tibshirani, R. J., Taidi, B., Czerwinski, D. K., & Levy, R. (2009) · Blood · doi:10.1182/blood-2009-01-201988 · Cited by 53
Vega, F., Medeiros, L. J., Lang, W., Mansoor, A., Bueso-Ramos, C., & Jones, D. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03497.x · Cited by 52
Dessureault, S., Noyes, D. R., Lee, D., Dunn, M. W., Janssen, W. E., Cantor, A. B., Sotomayor, E. M., Messina, J. L., & Antonia, S. J. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9196-4 · Cited by 50
CD4 CD25 Foxp3 regulatory T cells and hematologic malignancies
Kelley, T. W., & Parker, C. J. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s114 · Cited by 48
Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells
Brouwer, R. E., Zwinderman, K. H., Kluin-Nelemans, H. C., van Luxemburg-Heijs, S. A. P., Willemze, R., & Falkenburg, J. H. F. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(99)00143-5 · Cited by 46
Kitawaki, T., Kadowaki, N., Fukunaga, K., Kasai, Y., Maekawa, T., Ohmori, K., Kondo, T., Maekawa, R., Takahara, M., Nieda, M., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08490.x · Cited by 38
Lokhorst, H. M., Plesner, T., Gimsing, P., Nahi, H., Minnema, M., Lassen, U. N., Krejcik, J., Laubach, J., Lisby, S., Basse, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8512 · Cited by 36
Witzig, T. E., Wiseman, G. A., Maurer, M. J., Habermann, T. M., Micallef, I. N., Nowakowski, G. S., Ansell, S. M., Colgan, J. P., Inwards, D. J., Porrata, L. F., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23460 · Cited by 36
Qazilbash, M. H., Wieder, E., Thall, P. F., Wang, X., Rios, R. L., Lu, S., Kant, S., Giralt, S. A., Estey, E. H., Cortes, J. E., et al. (2007) · Blood · doi:10.1182/blood.v110.11.283.283 · Cited by 31
Posttransplantation Vaccination: Concepts Today and on the Horizon
Rezvani, K. (2011) · Hematology · doi:10.1182/asheducation-2011.1.299 · Cited by 26
Viardot, A., Goebeler, M., Heß, G., Neumann, S., Pfreundschuh, M. G., Adrian, N., Zettl, F., Libicher, M., Degenhard, E., Stieglmaier, J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4460.4460 · Cited by 23
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia
Reagan, J. L., & Castillo, J. J. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.223 · Cited by 17
Davids, M. S., Kim, H. T., Costello, C. L., Avigan, D., Chen, Y., Armand, P. A., Alyea, E. P., Hedlund, J. A., McSweeney, P. A., Liguori, R., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3964.3964 · Cited by 17
Rojas, J. M., Knight, K., Watmough, S. J., Bell, J., Wang, L., Callaghan, T. A., & Clark, R. E. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.05.028 · Cited by 12
Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas
Muraro, E., Martorelli, D., & Dolcetti, R. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23970 · Cited by 10
Cited by
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Self-citationThe interaction of innate immune and adaptive immune system
Wang, R., Lan, C., Benlagha, K., Camara, N. O. S., Miller, H., Kubo, M., Heegaard, S., Lee, P., Yang, L., Forsman, H., et al. (2024) · MedComm · doi:10.1002/mco2.714 · Cited by 305
“168 In the innate immune system, tumor-associated macrophages (TAMs) play an important role in tumor suppression.”
BackgroundThe Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, L., Perez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodriguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221
“Growing knowledge about tumor and immune cell biology led to continuous development of immunotherapies against each of the four major nodes of vulnerability in the cancer–immune relationship: direct targeting of surface antigens; boosting of numbers and functioning of immune effectors; activating tumor antigen-specifi…”
BackgroundImmunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 190
Metadata
- Authors
- Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Wu, Catherine J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-03-19
- Volume
- 15
- Issue
- 4
- Pages
- 201-215
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4511812
- OpenAlex
- W2083691419
- Cited by
- 85
- References
- 215
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 11 · 2016: 11 · 2015: 7
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL103532)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (P01CA206978, R01CA155010, T32CA009172, P30CA006516)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- hematologic malignancies, cancer immunotherapy, immune evasion, cancer immune response, immune checkpoint inhibitors, adoptive immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Hematologic Neoplasms, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.